{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mouth+Disease&page=21", "query": { "condition": "Mouth Disease", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 5918, "total_pages": 592, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mouth+Disease&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mouth+Disease&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T20:13:58.004Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01625182", "title": "Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Inflammatory Demyelinating Polyradiculoneuropathy" ], "interventions": [ { "name": "Fingolimod", "type": "DRUG" }, { "name": "Placebo Comparator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 106, "start_date": "2012-12-22", "completion_date": "2016-09-03", "has_results": true, "last_update_posted_date": "2017-10-30", "last_synced_at": "2026-10-25T20:13:58.004Z", "location_count": 12, "location_summary": "Orange, California • Miami, Florida • St. Petersburg, Florida + 9 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01625182" }, { "nct_id": "NCT00000689", "title": "Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin", "HIV Infections" ], "interventions": [ { "name": "Bleomycin sulfate", "type": "DRUG" }, { "name": "Vincristine sulfate", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Leucovorin calcium", "type": "DRUG" }, { "name": "Sargramostim", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 18, "start_date": null, "completion_date": "1991-03", "has_results": false, "last_update_posted_date": "2021-11-02", "last_synced_at": "2026-10-25T20:13:58.004Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000689" }, { "nct_id": "NCT00147550", "title": "MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Colonic Neoplasms", "Breast Neoplasms" ], "interventions": [ { "name": "PD-0325901", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2004-02", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2013-09-13", "last_synced_at": "2026-10-25T20:13:58.004Z", "location_count": 17, "location_summary": "Birmingham, Alabama • La Jolla, California • La Mesa, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00147550" }, { "nct_id": "NCT03622697", "title": "Effects of Mindfulness Meditation on Facial Paralysis Patients", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Facial Paralysis" ], "interventions": [ { "name": "Mindfulness Meditation Phone Application", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-07", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2021-10-19", "last_synced_at": "2026-10-25T20:13:58.004Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Lutherville-Timonium, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Lutherville-Timonium", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03622697" }, { "nct_id": "NCT01646840", "title": "Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PF-04958242 capsule", "type": "DRUG" }, { "name": "PF-04958242 oral solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 12, "start_date": "2012-07", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2019-11-21", "last_synced_at": "2026-10-25T20:13:58.004Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01646840" }, { "nct_id": "NCT02239120", "title": "Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stroke", "Secondary Prevention" ], "interventions": [ { "name": "optional ASA as comedication", "type": "DRUG" }, { "name": "placebo to ASA", "type": "DRUG" }, { "name": "placebo to optional ASA as comedication", "type": "DRUG" }, { "name": "placebo to dabigatran etexilate", "type": "DRUG" }, { "name": "ASA 100 mg", "type": "DRUG" }, { "name": "dabigatran etexilate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "150 Years", "sex": "ALL", "summary": "18 Years to 150 Years" }, "enrollment_count": 5390, "start_date": "2014-11-27", "completion_date": "2018-08-14", "has_results": true, "last_update_posted_date": "2019-09-06", "last_synced_at": "2026-10-25T20:13:58.004Z", "location_count": 110, "location_summary": "Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "El Cajon", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02239120" }, { "nct_id": "NCT02142582", "title": "Comparison of Different Oral Rehydration Solutions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Short Bowel Syndrome" ], "interventions": [ { "name": "WHO ORS", "type": "DIETARY_SUPPLEMENT" }, { "name": "Commercial ORS", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 28, "start_date": "2014-05", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2016-05-04", "last_synced_at": "2026-10-25T20:13:58.004Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02142582" }, { "nct_id": "NCT06794476", "title": "Milieu Teaching-AV (MT-AV Pilot)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Autism Sibling", "Autism Spectrum Disorder" ], "interventions": [ { "name": "Milieu Teaching-AV", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Father Flanagan's Boys' Home", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Months", "maximum_age": "12 Months", "sex": "ALL", "summary": "5 Months to 12 Months" }, "enrollment_count": 0, "start_date": "2026-03-18", "completion_date": "2026-03-18", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-10-25T20:13:58.004Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06794476" }, { "nct_id": "NCT00019110", "title": "Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anal Cancer", "Cervical Cancer", "Esophageal Cancer", "Head and Neck Cancer", "Penile Cancer", "Vulvar Cancer" ], "interventions": [ { "name": "human papillomavirus 16 E7 peptide", "type": "BIOLOGICAL" }, { "name": "synthetic human papillomavirus 16 E6 peptide", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "1995-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-29", "last_synced_at": "2026-10-25T20:13:58.004Z", "location_count": 6, "location_summary": "Bethesda, Maryland • Boston, Massachusetts • Morristown, New Jersey + 1 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019110" }, { "nct_id": "NCT01263197", "title": "A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "LY2216684", "type": "DRUG" }, { "name": "albuterol", "type": "DRUG" }, { "name": "propranolol", "type": "DRUG" }, { "name": "placebo for LY2216684", "type": "DRUG" }, { "name": "placebo for albuterol", "type": "DRUG" }, { "name": "placebo for propranolol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2010-12", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2019-01-29", "last_synced_at": "2026-10-25T20:13:58.004Z", "location_count": 1, "location_summary": "Evansville, Indiana", "locations": [ { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01263197" } ] }